Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

被引：47

作者：

Desai, Jayesh ^{[1
,2
]}

Alonso, Guzman ^{[3
]}

Kim, Se Hyun ^{[4
]}

Cervantes, Andres ^{[5
]}

Karasic, Thomas ^{[6
]}

Medina, Laura ^{[7
]}

Shacham-Shmueli, Einat ^{[8
]}

Cosman, Rasha ^{[9
,10
]}

Falcon, Alejandro ^{[11
]}

Gort, Eelke ^{[12
]}

Guren, Tormod ^{[13
]}

Massarelli, Erminia ^{[14
]}

Miller Jr, Wilson H. ^{[15
,16
]}

Paz-Ares, Luis ^{[17
,18
]}

Prenen, Hans ^{[19
]}

Amatu, Alessio ^{[20
]}

Cremolini, Chiara ^{[21
]}

Kim, Tae Won ^{[22
]}

Moreno, Victor ^{[23
]}

Ou, Sai-Hong I. ^{[24
]}

Passardi, Alessandro ^{[25
]}

Sacher, Adrian ^{[26
,27
,28
]}

Santoro, Armando ^{[29
,30
]}

Stec, Rafal ^{[31
,32
]}

Ulahannan, Susanna ^{[33
,34
]}

Arbour, Kathryn ^{[35
]}

Lorusso, Patricia ^{[36
]}

Luo, Jia ^{[37
]}

Patel, Manish R. ^{[38
]}

Choi, Yoonha ^{[39
]}

Shi, Zhen ^{[39
]}

Mandlekar, Sandhya ^{[39
]}

Lin, Mark T. ^{[39
]}

Royer-Joo, Stephanie ^{[39
]}

Chang, Julie ^{[39
]}

Jun, Tomi ^{[39
]}

Dharia, Neekesh V. ^{[39
]}

Schutzman, Jennifer L. ^{[39
]}

Han, Sae-Won ^{[40
,41
]}

机构：

[1] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[3] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[4] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea

[5] Hosp Clin Univ Valencia, Valencia, Spain

[6] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[7] Reg & Virgen de la Victoria Univ Hosp, Med Oncol Interctr Unit, IBIMA, Malaga, Spain

[8] Tel Aviv Univ, Sheba Med Ctr, Sackler Sch Med, Tel Aviv, Israel

[9] Univ New South Wales, St Vincents Hosp, Kinghorn Canc Ctr, Sydney, Australia

[10] Univ New South Wales, Sch Med, Sydney, Australia

[11] Hosp Univ Virgen del Rocio, Seville, Spain

[12] Univ Med Ctr Utrecht, Utrecht, Netherlands

[13] Oslo Univ Hosp, Radiumhosp, Oslo, Norway

[14] City Hope Comprehens Canc Ctr, Duarte, CA USA

[15] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ, Canada

[16] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ, Canada

[17] Univ Complutense, Hosp Univ 12 Octubre, H120 CNIO Lung Canc Unit, Madrid, Spain

[18] Ciberonc, Madrid, Spain

[19] Univ Hosp Antwerp, Edegem, Belgium

[20] Grande Osped Metropolitano Niguarda, Haematol & Oncol Div, Milan, Italy

[21] Univ Pisa, Pisa, Italy

[22] Univ Ulsan, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[23] Hosp Univ Fdn Jimenez Diaz, START MADRID FJD, Madrid, Spain

[24] Univ Calif Irvine, Sch Med, Chao Family Comprehens Canc Ctr, Orange, CA USA

[25] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Dept Med Oncol, Meldola, Italy

[26] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[27] Univ Toronto, Dept Med, Toronto, ON, Canada

[28] Univ Toronto, Dept Immunol, Toronto, ON, Canada

[29] Humanitas Univ, Milan, Italy

[30] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[31] Przychodnia Jozefow, Biokinet, Jozefow, Poland

[32] Warsaw Med Univ, Warsaw, Poland

[33] Stephenson Canc Ctr, Oklahoma City, OK USA

[34] Sarah Cannon Res Inst, Nashville, TN USA

[35] Mem Sloan Kettering Canc Ctr, New York, NY USA

[36] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[37] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[38] Sarah Cannon Res Inst, Florida Canc Specialists, Sarasota, FL USA

[39] Genentech Inc, South San Francisco, CA USA

[40] Seoul Natl Univ Hosp, Seoul, South Korea

[41] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea

来源：

NATURE MEDICINE | 2023年 / 30卷 / 1期

关键词：

KRAS G12C; MUTATIONS;

D O I：

10.1038/s41591-023-02696-8

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

KRAS G12C mutation is prevalent in similar to 4% of colorectal cancer (CRC) and is associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at 400 mg. Epidermal growth factor receptor has been recognized as a major upstream activator of RAS-MAPK signaling, a proposed key mechanism of resistance to KRAS G12C inhibition in CRC. Here, we report on divarasib plus cetuximab (epidermal growth factor receptor inhibitor) in patients with KRAS G12C-positive CRC (n = 29) from arm C of an ongoing phase 1b trial. The primary objective was to evaluate safety. Secondary objectives included preliminary antitumor activity. The safety profile of this combination was consistent with those of single-agent divarasib and cetuximab. Treatment-related adverse events led to divarasib dose reductions in four patients (13.8%); there were no treatment withdrawals. The objective response rate was 62.5% (95% confidence interval: 40.6%, 81.2%) in KRAS G12C inhibitor-naive patients (n = 24). The median duration of response was 6.9 months. The median progression-free survival was 8.1 months (95% confidence interval: 5.5, 12.3). As an exploratory objective, we observed a decline in KRAS G12C variant allele frequency associated with response and identified acquired genomic alterations at disease progression that may be associated with resistance. The manageable safety profile and encouraging antitumor activity of divarasib plus cetuximab support the further investigation of this combination in KRAS G12C-positive CRC.

引用

页码：271 / 278

页数：18

共 50 条

[41] Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
Emily Chan
Eunice L. Kwak
Jimmy Hwang
Marja Heiskala
Guillaume de La Bourdonnaye
Monica Mita
Cancer Chemotherapy and Pharmacology, 2015, 75 : 701 - 709
[42] Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
Chan, Emily
Kwak, Eunice L.
Hwang, Jimmy
Heiskala, Marja
de La Bourdonnaye, Guillaume
Mita, Monica
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 701 - 709
[43] Combination effect of the KRAS G12D-specific degrader ASP3082 with Cetuximab in xenograft models of colorectal and pancreatic cancer cells with KRAS G12D mutation
Iguchi, K.
Nagashima, T.
Inamura, K.
Nishizono, Y.
Yoshinari, T.
Hayakawa, M.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S86 - S86
[44] Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Gadgeel, S.
Rahman, A.
Osaghae, U.
Fernando, T. M.
Lin, M. T.
Koli, K.
Meyenberg, C.
Mathisen, M.
Skoulidis, F.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S349 - S349
[45] Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer.
Li, Jian
Huang, Jing
Ba, Yi
Cao, Baoshan
Luo, Suxia
Li, Wenhua
Song, Zhengbo
Zhu, Liangjun
Xiong, Jianping
An, Guangyu
Zhang, Yanqiao
Li, Zhihua
Li, Yongsheng
Gu, Yanhong
Li, Xingya
Huang, Chenghui
Fu, Qihan
Hu, Changlu
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 191 - 191
[46] KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis
A Ruzzo
C Cremolini
B Vincenzi
L Salvatore
D Santini
G Masi
I Stasi
E Canestrari
E Rulli
I Floriani
K Bencardino
N Galluccio
V Catalano
G Tonini
M Magnani
G Fontanini
F Basolo
A Falcone
F Graziano
British Journal of Cancer, 2009, 101 : 715 - 721
[47] Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial.
Badarinath, S
Mitchell, EP
Jennis, A
Graham, CD
Hansen, VL
Henderson, CA
Chen, TT
Langer, C
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 252S - 252S
[48] Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial.
Polikoff, J
Mitchell, EP
Badarinath, S
Graham, CD
Jennis, A
Chen, TT
Gustafson, TN
Langer, C
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 264S - 264S
[49] KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
Loupakis, F.
Ruzzo, A.
Cremolini, C.
Vincenzi, B.
Salvatore, L.
Santini, D.
Masi, G.
Stasi, I.
Canestrari, E.
Rulli, E.
Floriani, I.
Bencardino, K.
Galluccio, N.
Catalano, V.
Tonini, G.
Magnani, M.
Fontanini, G.
Basolo, F.
Falcone, A.
Graziano, F.
BRITISH JOURNAL OF CANCER, 2009, 101 (04) : 715 - 721
[50] Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6+cetuximab (FX plus C) or FOLFIRI plus cetuximab (FF plus C): The CECOG/CORE1.2.001 trial
Koza, I., Sr.
Wrba, F.
Vrbanec, D.
Ocvirk, J.
Ciuleanu, T. E.
Beslija, S.
Papamichael, D.
Messinger, D.
Zielinski, C. C.
Brodowicz, T.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →